Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H19N7O6.2H2O |
| Molecular Weight | 477.428 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.NC1=NC2=C(N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=N2)C(=O)N1
InChI
InChIKey=ODYNNYOEHBJUQP-LTCKWSDVSA-N
InChI=1S/C19H19N7O6.2H2O/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28;;/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30);2*1H2/t12-;;/m0../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H19N7O6 |
| Molecular Weight | 441.3975 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://pubs.acs.org/doi/abs/10.1021/ja01853a512 | https://www.ncbi.nlm.nih.gov/pubmed/28031963 | https://www.ncbi.nlm.nih.gov/pubmed/1560436
Curator's Comment: description was created based on several sources, including
http://pubs.acs.org/doi/abs/10.1021/ja01853a512 | https://www.ncbi.nlm.nih.gov/pubmed/28031963 | https://www.ncbi.nlm.nih.gov/pubmed/1560436
Folic Acid is a B complex vitamin containing a pteridine moiety linked by a methylene bridge to para-aminobenzoic acid, which is joined by a peptide linkage to glutamic acid. Conjugates of Folic Acid are present in a wide variety of foods, particularly liver, kidneys, yeast and leafy green vegetables. Commercially available Folic Acid is prepared synthetically. Folic Acid occurs as a yellow or yellowish-orange crystalline powder and is very slightly soluble in water and insoluble in alcohol. Aqueous solutions of Folic Acid are heat sensitive and rapidly decompose in the presence of light and/or riboflavin; solutions should be stored in a cool place protected from light. Folic Acid is effective in the treatment of megaloblastic anemias due to a deficiency of Folic Acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. Folic Acid is relatively nontoxic in man. Rare instances of allergic responses to Folic Acid preparations have been reported and have included erythema, skin rash, itching, general malaise, and respiratory difficulty due to bronchospasm. Endocyte is developing an intravenous (IV) formulation of folic acid, called Neocepri®, which is intended for the diagnosis of positive folate receptor-positive status in patients with ovarian cancer when administered prior to the radioactive medicine, technetium Tc99m Etarfolatide. The benefits of Neocepri® are its ability to reduce the background activity observed on single photon emission computed tomography (SPECT) imaging in most normal, nontarget tissues (e.g. intestines, liver, kidney, spleen), thereby improving the image quality of the scans. The product had been granted orphan drug designation in the EU. Endocyte had filed a conditional marketing authorization application (CMA) with the European Medicines Agency (EMA) for Neocepri®.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006760 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | FOLVITE Approved UseIndications and Usage. Folic Acid is effective in the treatment of megaloblastic anemias due to a deficiency of Folic Acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. Launch Date1947 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
25.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18551467/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
FOLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
76 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18551467/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
FOLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18551467/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
FOLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. | 2001-03 |
|
| Subnormal concentrations of serum cobalamin (vitamin B12) in cats with gastrointestinal disease. | 2001-02-24 |
|
| Hyperhomocysteinemia is associated with venous thrombosis in patients with short bowel syndrome. | 2001-02-24 |
|
| Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. | 2001-02-20 |
|
| [Folates, vitamin B12, homocysteine and neural tube defects]. | 2001-02-15 |
|
| Knowledge on periconceptional use of folic acid in women of British Columbia. | 2001-02-15 |
|
| Bioactivity of [6R]-5-formyltetrahydrofolate, an unusual isomer, in humans and Enterococcus hirae, and cytochrome c oxidation of 10-formytetrahydrofolate to 10-formyldihydrofolate. | 2001-02-15 |
|
| C677T variant form at the MTHFR gene and CL/P: a risk factor for mothers? | 2001-02-01 |
|
| A bifunctional dihydrofolate synthetase--folylpolyglutamate synthetase in Plasmodium falciparum identified by functional complementation in yeast and bacteria. | 2001-02 |
|
| Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. | 2001-02 |
|
| Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. | 2001-02 |
|
| Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. | 2001-02 |
|
| Homocysteine and stroke. | 2001-02 |
|
| The alpha folate receptor is highly activated in malignant pleural mesothelioma. | 2001-02 |
|
| No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. | 2001-02 |
|
| Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. | 2001-02 |
|
| Low seminal plasma folate concentrations are associated with low sperm density and count in male smokers and nonsmokers. | 2001-02 |
|
| Analysis of uracil DNA glycosylase in human colorectal cancer. | 2001-02 |
|
| Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: The Physicians' Health Study. | 2001-02 |
|
| Lowered weight gain during pregnancy and risk of neural tube defects among offspring. | 2001-02 |
|
| Folate reception by vegetative Dictyostelium discoideum amoebae: distribution of receptors and trafficking of ligand. | 2001-02 |
|
| Homocysteine, its metabolites, and B-group vitamins in renal transplant patients. | 2001-02 |
|
| Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells? | 2001-02 |
|
| Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. | 2001-02 |
|
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. | 2001-02 |
|
| Recent insights into the molecular genetics of the homocysteine metabolism. | 2001-02 |
|
| Homocysteine metabolism in renal failure. | 2001-02 |
|
| The folate cycle and disease in humans. | 2001-02 |
|
| Changes in markers of anemia and iron metabolism and how they are influenced by antianemics in postpartum period. | 2001-02 |
|
| Physical activity and risk for cardiovascular events in diabetic women. | 2001-01-16 |
|
| Folic acid and miscarriage: an unjustified link. | 2001-01-15 |
|
| Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells. | 2001-01-01 |
|
| [Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options]. | 2001-01 |
|
| Homocysteine--a novel risk factor for vascular disease. | 2001-01 |
|
| SLATE: a method for the superposition of flexible ligands. | 2001-01 |
|
| Preconceptual folic acid: opportunity for preconceptual counseling offers opportunity to help prevent neural tube defects. | 2001-01 |
|
| Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients. | 2001-01 |
|
| Diet and cancer: one view at the start of the millennium. | 2001-01 |
|
| Intravenous infusion of iron and tetrahydrofolate does not influence intrauterine uteroferrin and secreted folate-binding protein content in swine. | 2001-01 |
|
| Oral clefts and vitamin supplementation. | 2001-01 |
|
| Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. | 2001-01 |
|
| Relationships between homocysteine, folate and vitamin B12 levels with the methylenetetrahydrofolate reductase polymorphism, in Indians from Western Venezuela. | 2001-01 |
|
| [Theoretical construction of chemotherapeutic tactics for advanced or recurrent gastrointestinal carcinoma]. | 2001-01 |
|
| Characterization of three genes encoding enzymes of the folate biosynthetic pathway in Plasmodium falciparum. | 2001-01 |
|
| Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial. | 2001-01 |
|
| Homocysteine: a new cardiac risk factor? | 2001-01 |
|
| Nitrous oxide-induced cobalamin deficiency. | 2001-01 |
|
| Ascertainment of pregnancies terminated because of birth defects: effect on completeness of adding a new source of data. | 2001-01 |
|
| Gastric tube graft interposition as an oesophageal substitute. | 2001-01 |
|
| Exocrine pancreatic insufficiency in tropical sprue. | 2001 |
Patents
Sample Use Guides
Usual Adult Dose for Megaloblastic Anemia: 1 mg orally, intramuscularly, subcutaneously or IV once a day.
Nutritional Supplementation (Recommended daily allowance): Males: 400 mkg/day, Females: 400-800 mkg/day, Pregnant women: 600 mkg/day, Nursing women: 500 mkg/day, Upper limit: 1 mg/day.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:21:19 GMT 2025
by
admin
on
Mon Mar 31 23:21:19 GMT 2025
|
| Record UNII |
0S1T5C0JZL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135564683
Created by
admin on Mon Mar 31 23:21:19 GMT 2025 , Edited by admin on Mon Mar 31 23:21:19 GMT 2025
|
PRIMARY | |||
|
DTXSID20273931
Created by
admin on Mon Mar 31 23:21:19 GMT 2025 , Edited by admin on Mon Mar 31 23:21:19 GMT 2025
|
PRIMARY | |||
|
75708-92-8
Created by
admin on Mon Mar 31 23:21:19 GMT 2025 , Edited by admin on Mon Mar 31 23:21:19 GMT 2025
|
PRIMARY | |||
|
0S1T5C0JZL
Created by
admin on Mon Mar 31 23:21:19 GMT 2025 , Edited by admin on Mon Mar 31 23:21:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
![Structure of (2S)-2-[4-[bis[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzamido]pentanedioic acid](/img/8bae2c60-6f0d-4c71-8754-94a461c7e0e7.svg "Structure of (2S)-2-[4-[bis[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzamido]pentanedioic acid")
![Structure of N-[4-[(2-Amino-3,4-dihydro-7-methyl-4-oxo-6-pteridinyl)amino]benzoyl]-L-glutamic acid](/img/795e0609-2331-4292-bd47-b5a05d51c584.svg "Structure of N-[4-[(2-Amino-3,4-dihydro-7-methyl-4-oxo-6-pteridinyl)amino]benzoyl]-L-glutamic acid")
![Structure of N-[4-[[(4S)-4-[[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]amino]-4-carboxy-1-oxobutyl]amino]benzoyl]-L-glutamic acid](/img/f24ccfaf-0e11-4fca-818c-fb399349de15.svg "Structure of N-[4-[[(4S)-4-[[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]amino]-4-carboxy-1-oxobutyl]amino]benzoyl]-L-glutamic acid")
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |